Jiao Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiao Wu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Huan Li
Department of Gastroenterology, Affliated Hospital of Southwest Medical University, Street Taiping No.25, Region Jiangyang, Luzhou, 646099, Sichuan Province, China
1 shared publication - Qing Li
Department of Gastroenterology, Affliated Hospital of Southwest Medical University, Street Taiping No.25, Region Jiangyang, Luzhou, 646099, Sichuan Province, China
1 shared publication - Shu Huang
Department of Gastroenterology, Lianshui People's Hospital Affiliated to Kangda College of Nanjing Medical University, Huai an, China
1 shared publication - Wei Peng
Department of Gastroenterology, Mianyang Central Hospital
1 shared publication - Xiangsheng Fu
Department of Gastroenterology, Clinical medical college and the first affiliated hospital of Chengdu medical college
1 shared publication - Xiaowei Tang
Department of Gastroenterology, the Affiliated Hospital of Southwest Medical University
1 shared publication
Latest Publications
- Open Access
- 19 June 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1860523
Intratumoral microbiome: a key regulator and novel therapeutic target for chemoresistance in pancreatic cancer
Pancreatic cancer is a highly lethal gastrointestinal malignancy with chemotherapy resistance as a major obstacle to improving prognosis. Emerging evidence indicates that the intratumoral microbiome is closely implicated in the development, progression, and therapeutic response of pancreatic cancer. The intratumoral microbiome of pancreatic cancer is mainly composed of Proteobacteria and Firmicutes , and its composition is significantly correlated with patient survival. Intratumoral microbes drive tumor progression by remodeling the immune microenvironment, inducing DNA damage, and activating oncogenic signaling pathways. Meanwhile, they exacerbate chemotherapy resistance via multiple mechanisms, including remodeling the extracellular matrix, establishing an immunosuppressive microenvironment, and metabolically inactivating chemotherapeutic agents. This review systematically summarizes the community composition of the intratumoral microbiome in pancreatic cancer, its regulatory effects, and underlying mechanisms on chemotherapy resistance, as well as the latest advances in targeted therapeutic strategies.
- 19 June 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1860523
Open AccessIntratumoral microbiome: a key regulator and novel therapeutic target for chemoresistance in pancreatic cancer
Pancreatic cancer is a highly lethal gastrointestinal malignancy with chemotherapy resistance as a major obstacle to improving prognosis. Emerging evidence indicates that the intratumoral microbiome is closely implicated in the development, progression, and therapeutic response of pancreatic cancer. The intratumoral microbiome of pancreatic cancer is mainly composed of Proteobacteria and Firmicutes , and its composition is significantly correlated with patient survival. Intratumoral microbes drive tumor progression by remodeling the immune microenvironment, inducing DNA damage, and activating oncogenic signaling pathways. Meanwhile, they exacerbate chemotherapy resistance via multiple mechanisms, including remodeling the extracellular matrix, establishing an immunosuppressive microenvironment, and metabolically inactivating chemotherapeutic agents. This review systematically summarizes the community composition of the intratumoral microbiome in pancreatic cancer, its regulatory effects, and underlying mechanisms on chemotherapy resistance, as well as the latest advances in targeted therapeutic strategies.
- Open Access
- 3 January 2019
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 14 (1) , 1
The 2 years’ long-term efficacy and safety of peroral endoscopic myotomy for the treatment of achalasia: a systematic review
In this retrospective review, we aimed to investigate the long-term efficacy and safety of POEM with follow-up period over 2 years. A systematic review related to POEM for achalasia was conducted. A literature search was performed in Pubmed, Medline, Ovid, Cochrane and EBSCO databases on November 2017. The following postoperative outcomes were extracted: Eckardt score, lower esophageal sphincter pressure, complications and clinical success. The total number of patients was 373. The mean operative time was 66.7 min and the overall rate of complications was 21.2%. The mean follow-up period was 30.0 months. The overall clinical success rate was 92.9% and the rate of gastroesophageal reflux disease was 10.2%. Rate of mortality after POEM was 0. Our study demonstrated that POEM is effective and safe for treating achalasia during the long-term followed up over 2 years.
- 3 January 2019
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 14 (1) , 1
Open AccessThe 2 years’ long-term efficacy and safety of peroral endoscopic myotomy for the treatment of achalasia: a systematic review
In this retrospective review, we aimed to investigate the long-term efficacy and safety of POEM with follow-up period over 2 years. A systematic review related to POEM for achalasia was conducted. A literature search was performed in Pubmed, Medline, Ovid, Cochrane and EBSCO databases on November 2017. The following postoperative outcomes were extracted: Eckardt score, lower esophageal sphincter pressure, complications and clinical success. The total number of patients was 373. The mean operative time was 66.7 min and the overall rate of complications was 21.2%. The mean follow-up period was 30.0 months. The overall clinical success rate was 92.9% and the rate of gastroesophageal reflux disease was 10.2%. Rate of mortality after POEM was 0. Our study demonstrated that POEM is effective and safe for treating achalasia during the long-term followed up over 2 years.